Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
35
MITPF Quote, Financials, Valuation and Earnings
Last price:
$6.75
Seasonality move
:
6.36%
Day range:
$6.75 - $6.75
52-week range:
$6.75 - $6.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$451.6M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingMithra Pharmaceuticals SA has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Mithra Pharmaceuticals SA has an estimated downside of -- from its current price of $6.75.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $6.75.
Fair Value
-
According to the consensus of 0 analysts, Mithra Pharmaceuticals SA has -- downside to fair value with a price target of -- per share.
MITPF vs. S&P 500
-
Over the past 5 trading days, Mithra Pharmaceuticals SA has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mithra Pharmaceuticals SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mithra Pharmaceuticals SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mithra Pharmaceuticals SA reported revenues of --.
Earnings Growth
-
Mithra Pharmaceuticals SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mithra Pharmaceuticals SA reported earnings per share of --.
Enterprise value:
607.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $115.1M | $168.1M | $144.9M | $106.4M | $101M | |
| Total Assets | $421.1M | $474M | $519.6M | $451.8M | $407.2M | |
| Current Liabilities | $36.8M | $40.8M | $56.1M | $133.1M | $96.8M | |
| Total Liabilities | $348.4M | $263.1M | $402.8M | $414M | $416.7M | |
| Total Equity | $72.7M | $210.9M | $116.7M | $37.7M | -$9.5M | |
| Total Debt | $30.3M | $28.6M | $161.7M | $181.6M | $181.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
MITPF
Sector
Market Cap
$451.6M
$44.6M
Price % of 52-Week High
100%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
--
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$6.75
200-day SMA
Sell
Level
$6.75
Bollinger Bands (100)
Sell
Level
6.75 - 6.75
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$6.75
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$6.75
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
4.7K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.
Stock Forecast FAQ
In the current month, MITPF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MITPF average analyst price target in the past 3 months is --.
-
Where Will Mithra Pharmaceuticals SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mithra Pharmaceuticals SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Mithra Pharmaceuticals SA?
Analysts are divided on their view about Mithra Pharmaceuticals SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mithra Pharmaceuticals SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Mithra Pharmaceuticals SA's Price Target?
The price target for Mithra Pharmaceuticals SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MITPF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mithra Pharmaceuticals SA is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MITPF?
You can purchase shares of Mithra Pharmaceuticals SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mithra Pharmaceuticals SA shares.
-
What Is The Mithra Pharmaceuticals SA Share Price Today?
Mithra Pharmaceuticals SA was last trading at $6.75 per share. This represents the most recent stock quote for Mithra Pharmaceuticals SA. Yesterday, Mithra Pharmaceuticals SA closed at $6.75 per share.
-
How To Buy Mithra Pharmaceuticals SA Stock Online?
In order to purchase Mithra Pharmaceuticals SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
